Insights into the therapeutic strategies for aging and aging-associated diseases
8 affiliations
- 1National University of Singapore (Suzhou) Research Institute, Suzhou, China
- 2Healthy Aging Research Center, Nutrilite Health Institute, Shanghai, China
- 3Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- 4Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- 5Institute of Quality Standards and Testing Technology for Agro-Products of Chinese Academy of Agricultural Sciences, Key Laboratory of Agro-food Safety and Quality, Ministry of Agriculture and Rural Affairs, Beijing, China. [email protected]
- 6Healthy Aging Research Center, Nutrilite Health Institute, Shanghai, China. [email protected]
- 7Department of Food Science & Technology, National University of Singapore, Singapore, Singapore. [email protected]
- 8National University of Singapore (Suzhou) Research Institute, Suzhou, China. [email protected]
Abstract
Aging is a complex biological process characterized by progressive functional decline, driving the incidence of age-related diseases such as neurodegeneration, metabolic disorders, and cardiovascular diseases. Therapeutic strategies targeting aging hallmarks can delay aging and mitigate disease risk. Emerging interventions focus on modulating core aging mechanisms, including cellular senescence, metabolic dysfunction, epigenetic alterations, and mitochondrial impairment, etc. Recent advances have focused on three strategies: senolytics (eliminating senescent cells, e.g., dasatinib + quercetin), senomorphics (inhibiting the senescence-associated secretory phenotype, e.g., rapamycin), and senoreversion (rejuvenating senescent cells via epigenetic reprogramming). Additionally, metabolic interventions such as caloric restriction mimetics (e.g., spermidine, α-ketoglutarate, ergothioneine) enhance mitochondrial function, activate autophagy, and reprogram energy metabolism, demonstrating lifespan extension and healthspan improvement in preclinical models. Collectively, these approaches hold promise for delaying aging and alleviating age-related pathologies, facilitating the transition to precision longevity medicine. Concurrently, artificial intelligence (AI) accelerates discovery by integrating multiomics data, predicting candidate compounds, identifying biomarkers, and enabling personalized interventions. Despite advancements, challenges remain in target specificity, off-target effects, and clinical translation. The convergence of AI, multitarget strategies, and precision medicine signals a transformative era in extending healthspan and combating aging-associated diseases. This review systematically summarizes current breakthroughs, clinical landscapes, and future directions in aging therapeutics, underscoring interdisciplinary strategies to redefine healthy aging.
Related
- Special Issue: Molecular Therapeutic Strategies in Allergic Diseases
- Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies
- Emerging Therapeutic Strategies for Neurodegenerative Diseases: A Comprehensive Review of Recent Advances and Future Directions
- Glutamine metabolic reprogramming in acute and chronic kidney diseases: mechanistic insights and therapeutic implications
- Editorial: The differentiation and reprogramming of tumor-associated myeloid cells and therapeutic strategies for cancer immunotherapy
BibTeX
@article{dong2026insights,
title = {{Insights into the therapeutic strategies for aging and aging-associated diseases}},
author = {Ruifang Dong and Qiming Wu and Juntao Kan and Caili Fu and Vincenzo Sorrentino and Ashley Chow and Yanan Lei and Di Wu and Zhenzhen Xu and Jun Du and Dejian Huang},
journal = {Signal Transduction and Targeted Therapy},
year = {2026},
month = jun,
doi = {10.1038/s41392-026-02662-z},
url = {https://doi.org/10.1038/s41392-026-02662-z},
note = {CC BY},
}
RIS
TY - JOUR
TI - Insights into the therapeutic strategies for aging and aging-associated diseases
AU - Ruifang Dong
AU - Qiming Wu
AU - Juntao Kan
AU - Caili Fu
AU - Vincenzo Sorrentino
AU - Ashley Chow
AU - Yanan Lei
AU - Di Wu
AU - Zhenzhen Xu
AU - Jun Du
AU - Dejian Huang
PY - 2026
DA - 2026/06/01
JO - Signal Transduction and Targeted Therapy
DO - 10.1038/s41392-026-02662-z
UR - https://doi.org/10.1038/s41392-026-02662-z
AB - Aging is a complex biological process characterized by progressive functional decline, driving the incidence of age-related diseases such as neurodegeneration, metabolic disorders, and cardiovascular diseases. Therapeutic strategies targeting aging hallmarks can delay aging and mitigate disease risk. Emerging interventions focus on modulating core aging mechanisms, including cellular senescence, metabolic dysfunction, epigenetic alterations, and mitochondrial impairment, etc. Recent advances have focused on three strategies: senolytics (eliminating senescent cells, e.g., dasatinib + quercetin), senomorphics (inhibiting the senescence-associated secretory phenotype, e.g., rapamycin), and senoreversion (rejuvenating senescent cells via epigenetic reprogramming). Additionally, metabolic interventions such as caloric restriction mimetics (e.g., spermidine, α-ketoglutarate, ergothioneine) enhance mitochondrial function, activate autophagy, and reprogram energy metabolism, demonstrating lifespan extension and healthspan improvement in preclinical models. Collectively, these approaches hold promise for delaying aging and alleviating age-related pathologies, facilitating the transition to precision longevity medicine. Concurrently, artificial intelligence (AI) accelerates discovery by integrating multiomics data, predicting candidate compounds, identifying biomarkers, and enabling personalized interventions. Despite advancements, challenges remain in target specificity, off-target effects, and clinical translation. The convergence of AI, multitarget strategies, and precision medicine signals a transformative era in extending healthspan and combating aging-associated diseases. This review systematically summarizes current breakthroughs, clinical landscapes, and future directions in aging therapeutics, underscoring interdisciplinary strategies to redefine healthy aging.
SN - 2059-3635
SN - 2095-9907
ER -